**Request For Use of Aggregate Data Form** 

Date of Submission (mm/dd/yy):	07/25/2019			
Name of Organization:	St. Mary's Medical Center			
Project Title:	An Examination of Clinical Outcomes Following			
	SBRT for Metastases from Primary Sarcomas			
Principal Investigator:	Sanjeev Sharma, M.D.			
Co-Investigators:	Raj Singh, M.D.			
-	Hayden Ansinelli, M.D.			
	Dana Sharma, B.S.			
Corresponding Contact Name:	Sanjeev Sharma, M.D.			
Contact Title:	Attending Radiation Oncologist, St. Mary's Medical			
	Center			
	Administrative Chair, Marshall University Joan C.			
	Edwards School of Medicine			
Contact Telephone Number:	304-360-3427			
Contact E-mail Address:	sharmalahr@comcast.net			
Contact Address:	4 Windsor Drive			
City, State, Zip:	Huntington, WV 25705			
Project Description				
Project Start Date (mm/dd/yy):	09/01/2019			
Project End Date (mm/dd/yy):	05/01/2020			
Type of Research Project:	□ Prospective Study			
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	x Retrospective Analysis			
	□ Technical Study			
	□ Other			
If "Other," please explain nature of project:				
What is the research question being asked?	How effective is SBRT at providing local control of metastases from primary sarcomas? What are the toxicities associated with treatment? Does dose escalation lead to improved local control or overall survival?			
What is the background or rationale for	escalation lead to improved local control or overall survival?  The role of SBRT in oligo-metastatic cancers is growing.			
What is the background or rationale for the research question? (if needed, please attach as a separate page to application)	escalation lead to improved local control or overall survival?  The role of SBRT in oligo-metastatic cancers is growing. However, seminal prospective studies have focus on carcinomas (i.e. lung, prostate, breast, colon) primaries with little data on the use of SBRT for metastatic sarcoma. We aim to address this gap through use of the RSS			
the research question? (if needed, please attach as a separate page to application)	escalation lead to improved local control or overall survival?  The role of SBRT in oligo-metastatic cancers is growing. However, seminal prospective studies have focus on carcinomas (i.e. lung, prostate, breast, colon) primaries with little data on the use of SBRT for metastatic sarcoma. We aim to address this gap through use of the RSS Registry			
the research question? (if needed, please	escalation lead to improved local control or overall survival?  The role of SBRT in oligo-metastatic cancers is growing. However, seminal prospective studies have focus on carcinomas (i.e. lung, prostate, breast, colon) primaries with little data on the use of SBRT for metastatic sarcoma. We aim to address this gap through use of the RSS Registry  Inclusion: patients with initial primary sarcomas treated			
the research question? (if needed, please attach as a separate page to application)	escalation lead to improved local control or overall survival?  The role of SBRT in oligo-metastatic cancers is growing. However, seminal prospective studies have focus on carcinomas (i.e. lung, prostate, breast, colon) primaries with little data on the use of SBRT for metastatic sarcoma. We aim to address this gap through use of the RSS Registry  Inclusion: patients with initial primary sarcomas treated with SBRT with minimal survival data, treatment data, and			
the research question? (if needed, please attach as a separate page to application)	escalation lead to improved local control or overall survival?  The role of SBRT in oligo-metastatic cancers is growing. However, seminal prospective studies have focus on carcinomas (i.e. lung, prostate, breast, colon) primaries with little data on the use of SBRT for metastatic sarcoma. We aim to address this gap through use of the RSS Registry  Inclusion: patients with initial primary sarcomas treated with SBRT with minimal survival data, treatment data, and follow-up data; all extra-cranial cases (including spine)			
the research question? (if needed, please attach as a separate page to application)  Patient Inclusion/Exclusion Criteria:	escalation lead to improved local control or overall survival?  The role of SBRT in oligo-metastatic cancers is growing. However, seminal prospective studies have focus on carcinomas (i.e. lung, prostate, breast, colon) primaries with little data on the use of SBRT for metastatic sarcoma. We aim to address this gap through use of the RSS Registry  Inclusion: patients with initial primary sarcomas treated with SBRT with minimal survival data, treatment data, and			
the research question? (if needed, please attach as a separate page to application)  Patient Inclusion/Exclusion Criteria:	escalation lead to improved local control or overall survival?  The role of SBRT in oligo-metastatic cancers is growing. However, seminal prospective studies have focus on carcinomas (i.e. lung, prostate, breast, colon) primaries with little data on the use of SBRT for metastatic sarcoma. We aim to address this gap through use of the RSS Registry  Inclusion: patients with initial primary sarcomas treated with SBRT with minimal survival data, treatment data, and follow-up data; all extra-cranial cases (including spine)  Exclusion: exclude SRS/brain metastases cases;			
the research question? (if needed, please attach as a separate page to application)  Patient Inclusion/Exclusion Criteria:  Data Requested  Description of patient population to be	escalation lead to improved local control or overall survival?  The role of SBRT in oligo-metastatic cancers is growing. However, seminal prospective studies have focus on carcinomas (i.e. lung, prostate, breast, colon) primaries with little data on the use of SBRT for metastatic sarcoma. We aim to address this gap through use of the RSS Registry  Inclusion: patients with initial primary sarcomas treated with SBRT with minimal survival data, treatment data, and follow-up data; all extra-cranial cases (including spine)  Exclusion: exclude SRS/brain metastases cases;			
the research question? (if needed, please attach as a separate page to application)  Patient Inclusion/Exclusion Criteria:	escalation lead to improved local control or overall survival?  The role of SBRT in oligo-metastatic cancers is growing. However, seminal prospective studies have focus on carcinomas (i.e. lung, prostate, breast, colon) primaries with little data on the use of SBRT for metastatic sarcoma. We aim to address this gap through use of the RSS Registry  Inclusion: patients with initial primary sarcomas treated with SBRT with minimal survival data, treatment data, and follow-up data; all extra-cranial cases (including spine) Exclusion: exclude SRS/brain metastases cases;  All patients with primary sarcomas treated with SBRT to metastatic sites			
the research question? (if needed, please attach as a separate page to application)  Patient Inclusion/Exclusion Criteria:  Data Requested  Description of patient population to be analyzed:  Time frame to be studied:	escalation lead to improved local control or overall survival?  The role of SBRT in oligo-metastatic cancers is growing. However, seminal prospective studies have focus on carcinomas (i.e. lung, prostate, breast, colon) primaries with little data on the use of SBRT for metastatic sarcoma. We aim to address this gap through use of the RSS Registry  Inclusion: patients with initial primary sarcomas treated with SBRT with minimal survival data, treatment data, and follow-up data; all extra-cranial cases (including spine) Exclusion: exclude SRS/brain metastases cases;  All patients with primary sarcomas treated with SBRT to metastatic sites  From registry inception to present			
the research question? (if needed, please attach as a separate page to application)  Patient Inclusion/Exclusion Criteria:  Data Requested  Description of patient population to be analyzed:  Time frame to be studied:  List exact data variables requested (i.e.	escalation lead to improved local control or overall survival?  The role of SBRT in oligo-metastatic cancers is growing. However, seminal prospective studies have focus on carcinomas (i.e. lung, prostate, breast, colon) primaries with little data on the use of SBRT for metastatic sarcoma. We aim to address this gap through use of the RSS Registry  Inclusion: patients with initial primary sarcomas treated with SBRT with minimal survival data, treatment data, and follow-up data; all extra-cranial cases (including spine) Exclusion: exclude SRS/brain metastases cases;  All patients with primary sarcomas treated with SBRT to metastatic sites			
the research question? (if needed, please attach as a separate page to application)  Patient Inclusion/Exclusion Criteria:  Data Requested Description of patient population to be analyzed: Time frame to be studied: List exact data variables requested (i.e. pathology, treatment planning	escalation lead to improved local control or overall survival?  The role of SBRT in oligo-metastatic cancers is growing. However, seminal prospective studies have focus on carcinomas (i.e. lung, prostate, breast, colon) primaries with little data on the use of SBRT for metastatic sarcoma. We aim to address this gap through use of the RSS Registry  Inclusion: patients with initial primary sarcomas treated with SBRT with minimal survival data, treatment data, and follow-up data; all extra-cranial cases (including spine) Exclusion: exclude SRS/brain metastases cases;  All patients with primary sarcomas treated with SBRT to metastatic sites  From registry inception to present  1. Treatment Planning (doses, fractions, number lesions, isodose lines, etc.)  2. Outcomes (survival, response, local control, KPS)			
the research question? (if needed, please attach as a separate page to application)  Patient Inclusion/Exclusion Criteria:  Data Requested  Description of patient population to be analyzed:  Time frame to be studied:  List exact data variables requested (i.e. pathology, treatment planning information, outcome, reimbursement,	escalation lead to improved local control or overall survival?  The role of SBRT in oligo-metastatic cancers is growing. However, seminal prospective studies have focus on carcinomas (i.e. lung, prostate, breast, colon) primaries with little data on the use of SBRT for metastatic sarcoma. We aim to address this gap through use of the RSS Registry  Inclusion: patients with initial primary sarcomas treated with SBRT with minimal survival data, treatment data, and follow-up data; all extra-cranial cases (including spine) Exclusion: exclude SRS/brain metastases cases;  All patients with primary sarcomas treated with SBRT to metastatic sites  From registry inception to present  1. Treatment Planning (doses, fractions, number lesions, isodose lines, etc.)  2. Outcomes (survival, response, local control, KPS)  3. Side-effects/related toxicities			
the research question? (if needed, please attach as a separate page to application)  Patient Inclusion/Exclusion Criteria:  Data Requested  Description of patient population to be analyzed:  Time frame to be studied:  List exact data variables requested (i.e. pathology, treatment planning	escalation lead to improved local control or overall survival?  The role of SBRT in oligo-metastatic cancers is growing. However, seminal prospective studies have focus on carcinomas (i.e. lung, prostate, breast, colon) primaries with little data on the use of SBRT for metastatic sarcoma. We aim to address this gap through use of the RSS Registry  Inclusion: patients with initial primary sarcomas treated with SBRT with minimal survival data, treatment data, and follow-up data; all extra-cranial cases (including spine) Exclusion: exclude SRS/brain metastases cases;  All patients with primary sarcomas treated with SBRT to metastatic sites  From registry inception to present  1. Treatment Planning (doses, fractions, number lesions, isodose lines, etc.)  2. Outcomes (survival, response, local control, KPS)			

instructions on data output (e.g., table specifications, sample tables).	7. Prio		treatments	(particularly
Deadline for receipt of data (mm/dd/yy):	10/01/2	019		

## **Data Use**

Are these data for internal research purposes only? (yes/no)	no
If requesting party will seek to share data with persons not already listed on this	
request, list the organizations with which	
data would be shared and in what	
capacity? (e.g., FDA for a clinical trial, NIH	
for a grant proposal, consultant for project	
development)	
Peer-reviewed publications to which	Radiotherapy and Oncology
submission is anticipated (if any)	
National meetings at which abstract	Potentially ASTRO 2020
presentation is anticipated (if any)	

## **Additional Submission Requirements**

Please attach each of the following:

- Copy of IRB approval letter for use of RSSearch® at your institution
- Curriculum vitae of the principal investigator

## **Requestor Certification**

In making this request, I certify that:

- All information provided on this form and attachments is accurate and complete;
- I have all requisite institutional authority to submit this Request for Use of Collaborative Data

Signature	Sanjeer Sharma M.D.
	Sanjeev Sharma, M.D.
Print Name	
	Attending Radiation Oncologist,
	St. Mary's Medical Center
Title	Administrative Chair,
	Marshall University Joan C. Edwards School of Medicine
	7/25/2019
Date	

Please submit Request for Use of Collaborative Data to <a href="mailto:jjenkins@therss.org">jjenkins@therss.org</a>

## For Internal Use Only:

Date application received:	7/25/19
	2019-0725
RSSearch Registry Request #	